Skip to search formSkip to main contentSkip to account menu

tasosartan

Known as: 5,8-dihydro-2,4-dimethyl-8-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)pyrido(2,3-d)pyrimidin-7(6H)-one, taso-sartan 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

Angiotensin II Type 1 Receptor BlockersPyrimidinesTetrazoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Strategies for Scaling up HIV prevention among Adolescents: TASO Masaka Safe Male Circumcision Experience
Issue: Uganda has HIV prevelance of 7.3%; however HIV prevalence in Masaka is at 10%. TASO Masaka has 383 active adolescents in… 
2016
2016
Suurin kestävä hakkuutaso
Valtakunnan tai jonkun pienemmän metsäalueen tai metsälön hakkuiden määrää verrataan usein joko kasvuun tai suurimpaan kestävään… 
2014
2014
The Role of a Special Prevention of Mother to Child Transmission Clinic in Improving Prevention, Care and Treatment of Infected and Exposed Infants; TASO Masaka Experience
AIDS: Acquired Immune Deficiency Syndrome; ART: Antiretroviral Therapy; CD4: Cluster of Differentiation; EID: Early Infant… 
2012
2012
PP138. Human fetal malformations associated with the use of angiotensin II receptor antagonist.
2010
2010
Disclosure of HIV status to sexual partners amongst people who receive antiretroviral treatment in Kampala, Uganda
The increased number of new infections in Uganda necessitates HIV prevention programmes that address risky behaviours especially… 
Review
2003
Review
2003
Review: angiotensin II receptor antagonists prevent headache in patients with mild-to-moderate hypertension.
Source Citation Etminan M, Levine MA, Tomlinson G, Rochon PA. Efficacy of angiotensin II receptor antagonists in preventing… 
1999
1999
The angiotensin AT(1) receptor antagonist irbesartan has near-peptide affinity and potently blocks receptor signaling.
1999
1999
Efficacy and tolerability of tasosartan, a novel angiotensin II receptor blocker: results from a 10-week, double-blind, placebo-controlled, dose-titration study. Tasosartan Investigators Group.
BACKGROUND Angiotensin II receptor antagonists are selective blockers of the renin-angiotensin system and represent an… 
1998
1998
Effects of angiotensin antagonism with tasosartan on regional and systemic haemodynamics in hypertensive patients
Objective Evaluate the effects of 2 weeks of treatment with tasosartan (1) on cardiac function at rest and during submaximal… 
1998
1998
FDA Panel report: January 1998.
The Cardiovascular and Renal Advisory Panel of the FDA met January 27-28, 1998, to discuss (1) evaluation and use of intravenous… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)